HOME >> MEDICINE >> NEWS
Antabuse May Inhibit Fatal Reaction To Anesthetic

UW researchers have concluded studies that may eliminate a fatal problem associated with what is historically one of the most widely used anesthetic agents in the world.

In approximately one in 30,000 patients, the anesthetic agent halothane causes a condition known as "halothane hepatitis," which results in swift and fatal liver damage in approximately 50 percent of cases. For four decades, this problem has been recognized in anesthesia, yet the mechanism by which it occurs has been incompletely understood.

Drug metabolism is the process by which our bodies transform and eliminate the foreign compounds. Halothane is transformed in the liver into a molecule that binds to liver proteins. In most people, this process has no significance, but in some people these liver proteins stimulate the formation of antibodies that seriously damage the liver. The reason why some patients are susceptible remains a mystery.

In a study published in the Lancet in 1996, Dr. Evan Kharasch, professor of anesthesiolofy, identified P450 2E1 as the enzyme responsible for the metabolic step that triggers the formation of antibodies. More recently, Kharasch and colleagues have shown that they can chemically inhibit P450 2E1 from carrying out this unwanted intracellular mission by giving patients a drug called disulfiram before anesthesia.

"We manipulate the activity of the enzyme with disulfiram, known by the trade name Antabuse. We found that a single dose could 'turn off' P450 2E1," Kharasch said.

The disulfiram is itself transformed in the liver into a chemical that inactivates P450 2E1 by binding to it and preventing its catalytic activity. "By turning off this enzyme we can prevent the molecular pathway leading to halothane toxification, and by extrapolation, possibly prevent halothane hepatitis," he said.

Kharasch has identified the role of p450 2E1 in the metabolism of several other volatile anesthetics. The
'"/>

Contact: Will Morton
wmmorton@u.washington.edu
206-543-3620
University of Washington
3-Dec-1998


Page: 1 2

Related medicine news :

1. Inhibitors prevent aggresome formation associated with some forms of ALS
2. Inhibiting Growth Of New Blood Vessels Reduces Heart Disease Plaque In Mice
3. Acetylcholinesterase Inhibitors May Be Another Piece In Alzheimers Jigsaw
4. New Protease Inhibitor Could Thwart AIDS Resistance To Current Drugs
5. Hunter College Biologist Marie Filbin Identifies Mechanism That Blocks All Inhibitors Of Nerve Regeneration; Breakthrough Reported In Neuron Magazine
6. Dynavax Demonstrates Ability Of Immunostimulatory DNA Sequences To Inhibit Symptoms Of Allergic Asthma In Animal Model
7. HIV Patients Treated With Protease Inhibitors Are More Likely To Engage In Risky Sex, Emory Researchers Report
8. Only Eight Percent Of San Francisco HIV-Positive Urban Poor Receive Protease Inhibitors
9. Answers To Access, Adherence And Tolerance Of Protease Inhibitors
10. ACE-Inhibitors Score High In Reducing Heart Attack Deaths
11. Declining National Rates Of HIV-Related Deaths And Illnesses Due To Combination Antiretroviral Therapy With Protease Inhibitors

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/16/2018)... ... 2018 , ... Author and thought leader in health and ... of Medicine (GreenLeaf Press, 2018) was recently awarded a gold medal from Readers' ... personal patient stories with a historical overview that reveals interesting and untold details ...
(Date:11/16/2018)... , ... November 16, 2018 , ... ... and other ailments through intravenous medications and antioxidants, has changed its name to ... hydration. , “While we’ve always focused on IV therapy and IV hydration through ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... a historic agreement with Taikang Healthcare in China to provide clinical and management ... Hospital in Nanjing, the capital of Jiangsu Province in east central China. , ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... Online Master's in Educational Psychology Programs for 2019. They have identified the top ... quality, program flexibility, affordability, and graduate outcomes. , Leveraging an exclusive data set ...
(Date:11/15/2018)... Tree, CO (PRWEB) , ... November 15, 2018 ... ... is pleased to announce the addition of platelet-rich plasma (PRP) therapies to her ... aesthetic treatments on the market, providing intense, all-natural revitalization for any area of ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... ... November 15, 2018 , ... American Bancard, dba TouchSuite ... U.S. and Canadian markets. TouchSuite will underwrite merchants selling CBD products online ... and understanding of the risks associated with the industry. CBD accounts will be ...
(Date:11/15/2018)... ... November 15, 2018 , ... Registration is now open ... the only case management conference enriching the entire healthcare continuum. The conference is ... NV. Industry professionals will convene to elevate their careers and experience an event ...
(Date:11/15/2018)... ... 2018 , ... Litmus Health , the research-ready infrastructure ... a $225,000 Phase I Small Business Innovation Research (SBIR) contract from the National ... of useful, well-structured data gathered outside the clinic has been a longstanding priority ...
Breaking Medicine Technology:
Cached News: